SGT 003
Alternative Names: SGT-003Latest Information Update: 08 Apr 2024
At a glance
- Originator Solid Biosciences
- Class Gene therapies
- Mechanism of Action Dystrophin replacements; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Duchenne muscular dystrophy
Most Recent Events
- 05 Apr 2024 Phase-I/II clinical trials in Duchenne muscular dystrophy (In children) in USA (IV) (NCT06138639)
- 01 Apr 2024 Solid Biosciences announces intention to submit BLA for Duchenne muscular dystrophy
- 01 Apr 2024 SGT 003 receives Rare Pediatric Disease Designation for Duchenne muscular dystrophy in USA